Even though we focused on CCDC80 in the present study, it would be worth investigating whether ITM2A and SFRP1 are involved in the action of combination treatment of vactosertib with nal-IRI/5-FU/LV in ameliorating pancreatic cancer. This evidence concerns the gene ITM2A and pancreatic neoplasm.